(Q36895818)

16 August 2017

1 reference

title

Blood biomarkers for prostate cancer detection and prognosis (English)

1 reference

16 August 2017

0 references

1 reference

1

Shahrokh F Shariat

1 reference

16 August 2017

3

Claus G Roehrborn

1 reference

16 August 2017

Jose A Karam

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

449-461

1 reference

16 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Free prostate-specific antigen in serum is becoming more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

The new human tissue kallikrein gene family: structure, function, and association to disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Early identification of individuals with prostate cancer in negative biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

EPCA-2: a highly specific serum marker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Interleukin-6: a candidate mediator of human prostate cancer morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Serum chromogranin-A in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.449

21 January 2018

Identifiers

DOI

10.2217/14796694.3.4.449

1 reference

16 August 2017

1 reference